Yazhou Li
National Institutes of Health(US)Institute on Aging(US)National Institute on Aging(US)
Research Areas
Diabetes Treatment and Management, Parkinson's Disease Mechanisms and Treatments, Traumatic Brain Injury and Neurovascular Disturbances, Neuropeptides and Animal Physiology, Alzheimer's disease research and treatments
Most-Cited Works
- → Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial(2017)821 cited
- → Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis(2002)589 cited
- → GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism(2009)574 cited
- → GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease(2010)320 cited
- → Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders(2012)256 cited
- → Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease(2019)245 cited
- → β-Cell Pdx1 Expression Is Essential for the Glucoregulatory, Proliferative, and Cytoprotective Actions of Glucagon-Like Peptide-1(2005)242 cited
- → Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment(2022)233 cited
- → Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease(2012)213 cited
- → Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis(2022)198 cited